Drug Trial Radar · NCT00799760
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
Last checked: Nov 20, 2026Latest source record: Mar 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
541
Actual
Start
Dec 2008
Primary completion
Nov 2009
Study completion Nov 2010
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hoffmann-La Roche; GlaxoSmithKline
- First posted
- Dec 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2.
Conditions
- Gastric Influenza
Interventions
oseltamivir + zanamivirDrug
oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
oseltamivir + zanamivir's placeboDrug
oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
oseltamivir's placebo + zanamivirDrug
oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
Primary outcomes
What the sponsor says the trial is designed to measure.
- RT-PCR for influenza A virus in nasal secretionTime frame: 2 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Investigateur 155
Deûlémont, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.